MedTrace Logo

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

NCT01551056 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2017-11-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

AC-170 0.24%

1 drop in each eye at 2 separate times during a 14 day period

DRUG

AC-170 0%

1 drop in each eye at 2 separate times during a 14 day period

Sponsors & Collaborators

  • Aciex Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jack Greiner, DO · Charles River Eye Associates

  • Gail Torkildsen · Andover Eye Associates

  • Stacey Ackerman, MD · Philadelphia Eye Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01551056 on ClinicalTrials.gov